Microbiome and Probiotics in Acne Vulgaris-A Narrative Review
Microbiome and Probiotics in Acne Vulgaris-A Narrative Review
Microbiome and Probiotics in Acne Vulgaris-A Narrative Review
Review
Microbiome and Probiotics in Acne Vulgaris—A Narrative Review
Karolina Chilicka 1, * , Iwona Dzieńdziora-Urbińska 1 , Renata Szyguła 1 , Binnaz Asanova 2
and Danuta Nowicka 3
Abstract: Acne vulgaris is a chronic disease characterised by the appearance of eruptions such
as whiteheads, blackheads, pustules, papules, and cysts. Among factors that cause acne vulgaris
are the abnormal keratinisation of the sebaceous canal, bacterial colonisation (Cutibacterium acnes),
increased sebum production, genotypic factors, and hormonal disorders. Treatment is often long and
tedious, and can lead to a reduction in quality of life and social isolation. The intestinal microbiota
is greatly important in the formation of acne lesions. It is also responsible for the proper immunity
of the organism. Acne is a disease that can be related to the condition of the digestive tract and its
microbiome. Research shows that the use of probiotics may reduce skin eruptions. The probiotic
supplementation and cosmetics markets are very dynamically developing. The use of internal
supplementation and probiotic-containing cosmetics gives hope for the improvement of the skin
condition of people with acne.
array of adverse effects, and only practitioners who are experienced with its use should pre-
scribe it. It may cause arthralgias, stiffness, tendonitis, serum lipid abnormalities, alopecia,
photosensitivity, mucosal and skin dryness, liver function test abnormalities, pancreati-
tis, depression, anaemia, and leukopenia. Laboratory tests, including serum cholesterol,
triglycerides, high-density lipoprotein, liver function tests, and a complete blood count,
should be performed before the initiation of isotretinoin therapy and periodically during
treatment, generally every 4–6 weeks. Of particular concern is the risk to pregnant women,
as isotretinoin is associated with spontaneous abortion and congenital malformations. Its
teratogenicity mandates that appropriate screening and counselling be conducted before
initiating therapy in women of childbearing age. Urine or serum pregnancy tests should be
performed in the week before starting therapy and should monthly throughout treatment.
The use of two methods of birth control is recommended; contraception should be practised
from 1 month before starting therapy until 1 month after it is discontinued.
As a result of long-term treatment and severe forms of acne, scars can remain on
patient skin and reduce quality of their life. Symptoms caused by acne contribute to the
development of depression, especially in adolescents. Post inflammatory hyperpigmen-
tation can cause fears that lead to deterioration of quality of life. It is very important to
contact a dermatologist who could professionally assess the causes of acne and select the
appropriate treatment that prevents complications such as discoloration or acne scars [2].
Androgen hormones and testosterone control sebum production. Patients with severe
acne, both men and women, have increased levels of dehydroepiandrosterone sulphate,
sex hormone-binding globulin, and androstenedione. Excessive sebum production plays a
key role in the pathophysiology of acne and generates the inflammatory process [3].
Researchers claim that there is a relationship between acne and the consumption of
milk or other dairy products. There is the hypothesis that consuming highly glycaemic
food and milk can increase the level of insulin. This can lead to inflammation, androgenic
stimulation, and the formation of blackheads and whiteheads [4].
2. Skin Microbiome
The term microbiome (microbiota) describes the entirety of microorganisms present
in a given habitat. The skin is the most external organ of our body and is inhabited by
bacteria, viruses, fungi, and mites. Most of the microorganisms that inhabit the skin are
harmless to the skin and live in symbiosis with skin cells [5–8].
The main types of dermal colonisation are the following bacteria: Actinobacteria (Mi-
crococcus spp.), Firmicutes (nonhaemolytic aerobes and anaerobes), Staphylococci (Staphy-
lococcus spp.), Clostridium spp., ahaemolytic Streptococci (Streptococcus spp.), Enterococci
(Enterococcus spp., Sphingobacterium spp., Chryseobacterium spp.), Proteobacteria (Janthinobac-
terium spp., Serratia spp., Halomonas spp., Delftia spp., Comamonas spp.) [9,10]. Bacteria
inhabiting the surface of the skin include S. epidermidis, S. saprophyticus, S. hominis, S. warneri,
S. haemolyticus, and S.capitis, bacteria of the genus Cutibacterium (C. acnes, C. jeikeium) and
bacteria of the genus Micrococcus (M. luteus, M. varians, M. lylae, M. sedentarius, M. roseus,
M. kristinae, and M. nishinomiyaensis). The skin can also be inhabited by pathogenic bacteria
such as group A Streptococci (S. pyogenes) and Gram-negative bacilli (P. aeruginosa) [11,12].
On the surface of human skin, there are also fungi of genera Malassezia (M. furfur,
M. sympodialis, M. globosa, M. restricta, M. slooffiae, M. yamatoensis, M. obtusa, M. dermatis,
and M. japonica), Penicillium (P. chrysogenum, P. lanosum), Aspergillus (A. candidus, A. terreus,
A. versicolor), Candida (C. tropicalis, C. parapsilosis, C.orthopsilosis), Chaetomium, Chrysospo-
rium, Cladosporium, Mucor, Debaryomyces, Cryptococcus (C. flavus, C. dimmennae, C.diffluent),
Trichophyton and Rhodotorula. Pathogenic fungi that are capable of causing skin diseases
include the following dermatophytes (Microsporum, Trichophyton, Epidermophyton) [9,13–16].
As mentioned above, the skin microbiome also includes mites. Demodex spp. are
characteristic of sebaceous glands and hair follicles, with the most numerous representatives
being D. folliculorum (hair follicles), D. brevis (sebaceous glands and Meibomian glands).
Life 2022, 12, 422 3 of 11
with its ability to improve oxidative stress parameters, could also change the microflora
of the skin and improve its condition. The association among psoriasis, changes in skin
microbiota, and systemic oxidative stress parameters after narrowband UVB therapy is an
interesting topic of further research.
The exact pathophysiology of rosacea is still poorly understood, but current theories
focus on the role of the cutaneous microbiome, specifically D. folliculorum and a few
commensal bacteria, in the propagation of an inflammatory response. However, the theory
of microbial induction extends beyond the skin to include the gastrointestinal microbiome
and complications therein. Additional gastrointestinal pathologies have been implicated,
including infection by H.pylori and irritable bowel syndrome. The treatment of rosacea
with topical antibiotics and antiparasitic agents has long reigned supreme, followed by oral
agents of the tetracycline class. Future studies should further investigate the role of the
gastrointestinal microbiome in the pathogenesis of rosacea, as intraluminal agents such as
rifaxim in have beneficial effects.
In hidradenitis suppurativa, also called acne inversa, dysregulated microbiome is
mentioned among other causative factors [30]. Research reports differences between
lesional and nonlesional skin in people with and without hidradenitis suppurativa in terms
of the composition of the skin microbiome. In patients with hidradenitis suppurativa, the
microbiome of skin lesions included Cutibacterium species, Porphyromonas and Peptoniphilus
species, while in the microbiome of nonlesional skin, Acinetobacter and Moraxella species
dominated. No C. acnes was found in patients with hidradenitis suppurativa [31]. Evidence
of differences in the composition of the gastrointestinal microbiome is limited but suggests
that the gut microbiome of patients with hidradenitis suppurativa may be altered when
compared to that of healthy people [32].
C. acnes, due to the presence of lipase, hydrolyses di- and triglycerides that are part of sebum
into free fatty acids, have an irritating and proinflammatory effect, and intensify follicular
keratosis. Additionally, C. acnes produces protease hyaluronidase and neuraminidases,
which also have a proinflammatory effect. In the pathogenesis of acne, insulin growth
factor 1(IGF-1) stimulating the production of sebum also plays a role. It increases skin
eruptions in women, while in men, it causes seborrhoea [45]. C. acnes and a hyperglycaemic
diet stimulate the proliferation of keratinocytes and the formation of comedones [46].
Human skin is colonised by many microbes, and although C. acnes is most associated
with acne eradication, other microbes also influence the development of this disease. On
the basis of scientific studies, C. granulosum is more virulent than C. acnes, and is found
in comedones and pustules in acne patients [47]. Malassezia is also believed to be an acne-
causing organism [48]. Many studies showed that Malassezia also hydrolyses triglycerides to
free fatty acids, which cause hyperkeratinisation of the hair follicle ducts and the formation
of comedones [49].
limitations and methods of skin sampling indicate the need for more extensive research in
this area.
sunbathing. Probiotics also protect the skin of the hands and the nail plate, and have an
anti-itching effect. Research shows that the use of probiotics also has a favourable effect on
the regulation of pH thanks to the use of facial cleansing fluids, peels, and toning prepa-
rations [77,78]. The use of preparations influences the development of normal microflora,
thanks to which a protective barrier is created. The epidermis maintains adequate moisture
and strengthens the skin’s resistance to all negative external factors. The use of bacteria
such as Streptococcus salivarium spp. and S. thermophilus S244 in cosmetics leads to the
production of enzymes that moisturise the skin, thus reducing skin dryness and slowing
down ageing processes [79].
7. Conclusions
Acne is a skin disease with an inflammatory background. Using antibiotics or
isotretinoin has a negative effect on the intestinal flora. Patients with severe acne are
frequently treated with oral isotretinoin (13-cis-retinoic acid), often with dramatic results.
Isotretinoin is an ideal medication based on its mechanisms of action, which include a
reduction in sebum production, the inhibition of comedo formation, and modulation of the
inflammatory response; a course of therapy may lead to prolonged remission even in the
most severe cases. Unfortunately, isotretinoin is associated with a wide array of adverse
effects, and only practitioners who are experienced with its use should prescribe it. It may
cause arthralgias, stiffness, tendonitis, serum lipid abnormalities, alopecia, photosensitiv-
ity, mucosal and skin dryness, liver function test abnormalities, pancreatitis, depression,
anaemia, and leukopenia. Scientists are constantly looking for new solutions that would
bring good results when it comes to the treatment of acne. Research shows that the use
of probiotics may reduce skin eruptions. The intestinal microbiota is greatly important
in the formation of acne lesions. It is also responsible for the proper immunity of the
organism. Acne is a disease that can be linked to the condition of the digestive tract and
its microbiome. Research shows that the use of probiotics may reduce skin eruptions. The
probiotic supplementation and cosmetics markets are dynamically developing. The use of
internal supplementation and cosmetics with probiotics give hope for the improvement of
the skin condition of people suffering from acne.
Author Contributions: Conceptualisation and methodology, K.C., D.N. and I.D.-U.; formal analysis,
K.C., D.N. and I.D.-U.; writing—original draft preparation, K.C., D.N., I.D.-U., R.S. and B.A.; writing—
review and editing, K.C. and D.N. All authors have read and agreed to the published version of
the manuscript.
Funding: This research received no external funding.
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Data Availability Statement: Not applicable.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Chilicka, K.; Rogowska, A.M.; Szyguła, R.; Dzieńdziora-Urbińska, I.; Taradaj, J. A comparison of the effectiveness of azelaic and
pyruvic acid peels in the treatment of female adult acne: A randomized controlled trial. Sci. Rep. 2020, 10, 12612. [CrossRef]
[PubMed]
2. Gieler, U.; Gieler, T.; Kupfer, J.P. Acne and quality of life—Impact and management. J. Eur. Acad. Dermatol. Venereol. 2015, 29
(Suppl. S4), 12–14. [CrossRef] [PubMed]
3. Ray, C.; Trivedi, P.; Sharma, V. Acne and its treatment lines. Int. J. Res. Pharma. Sci. 2013, 1, 1–16.
4. Melnik, B.C. Evidence for acne-promoting effects of milk and other insulinotropic dairy products. Nestlé Nutr. Workshop Ser.
Pediatric Program 2011, 67, 131–145.
5. Grice, E.A.; Segre, J.A. The skin microbiome. Nat. Rev. Microbiol. 2011, 9, 244–253. [CrossRef] [PubMed]
6. Belkaid, Y.; Hand, T.W. Role of the microbiota in immunity and inflammation. Cell 2014, 157, 121–141. [CrossRef] [PubMed]
7. Malinowska, M.; Tokarz-Deptuła, B.; Deptuła, W. Mikcobiome of the men. Post Mikrobiol. 2017, 56, 33–42.
8. Adamczyk, K.; Garncarczyk, A.A.; Antończak, P.P. The microbiome of the skin. Dermatol. Rev./Przegl. Dermatol. 2018, 105, 285–297.
[CrossRef]
9. Rahim, K.; Saleha, S.; Zhu, X.; Huo, L.; Basit, A.; Franco, O.L. Bacterial Contribution in Chronicity of Wounds. Microb. Ecol. 2017,
73, 710–721. [CrossRef]
10. Findley, K.; Oh, J.; Yang, J.; Conlan, S.; Deming, C.; Meyer, J.A.; Schoenfeld, D.; Nomicos, E.; Park, M.; Becker, J.; et al. Topographic
diversity of fungal and bacterial communities in human skin. Nature 2013, 498, 367–370. [CrossRef]
11. Percival, S.L.; Emanuel, C.; Cutting, K.F.; Williams, D.W. Microbiology of the skin and the role of biofilms in infection. Int. Wound
J. 2012, 9, 14–32. [CrossRef] [PubMed]
12. Grice, E.A.; Kong, H.H.; Conlan, S.; Deming, C.B.; Davis, J.; Young, A.C.; Program, N.C.S.; Bouffard, G.G.; Blakesley, R.W.;
Murray, P.R.; et al. Topographical and temporal diversity of the human skin microbiome. Science 2009, 324, 1190–1192. [CrossRef]
[PubMed]
Life 2022, 12, 422 9 of 11
13. Schommer, N.N.; Gallo, R.L. Structure and function of the human skin microbiome. Trends Microbiol. 2013, 21, 660–668. [CrossRef]
[PubMed]
14. Gaitanis, G.; Magiatis, P.; Hantschke, M.; Bassukas, I.D.; Velegraki, A. The Malassezia genus in skin and systemic diseases. Clin.
Microbiol. Rev. 2012, 25, 106–141. [CrossRef] [PubMed]
15. Glatz, M.; Bosshard, P.P.; Hoetzenecker, W.; Schmid-Grendelmeier, P. The role of Malassezia spp. in atopic dermatitis. J. Clin. Med.
2015, 4, 1217–1228. [CrossRef]
16. Jagielski, T.; Rup, E.; Macura, A.B.; Bielecki, J. Characterization of fungi of the Malassezia genus. I. Microbiological and immuno-
logical aspect. Post Mikrobiol. 2013, 52, 295–305.
17. Ellis, S.R.; Nguyen, M.; Vaughn, A.R.; Notay, M.; Burney, W.A.; Sandhu, S.; Sivamani, R.K. The Skin and Gut Microbiome and Its
Role in Common Dermatologic Conditions. Microorganisms 2019, 7, 550. [CrossRef]
18. Bikowski, J.B.; Del Rosso, J.Q. Demodex dermatitis: A retrospective analysis of clinical diagnosis and successful treatment with
topical crotamiton. J. Clin. Aesthet. Dermatol. 2009, 2, 20–25.
19. Kong, H.H.; Andersson, B.; Clavel, T.; Common, J.E.; Jackson, S.A.; Olson, N.D.; Segre, J.A.; Traidl-Hoffmann, C. Performing skin
microbiome research: A method to the madness. J. Investig. Dermatol. 2017, 137, 561–568. [CrossRef]
20. Oh, J.; Byrd, A.L.; Park, M.; Kong, H.H.; Segre, J.A.; NISC Comparative Sequencing Program. Temporal stability of the human
skin microbiome. Cell 2016, 165, 854–866. [CrossRef]
21. Liang, G.; Bushman, F.D. The human virome: Assembly, composition and host interactions. Nat. Rev. Microbiol. 2021, 19, 514–527.
[CrossRef] [PubMed]
22. Hannigan, G.D.; Meisel, J.S.; Tyldsley, A.S.; Zheng, Q.; Hodkinson, B.P.; SanMiguel, A.J.; Minot, S.; Bushman, F.D.; Grice, E.A. The
human skin double-stranded DNA virome: Topographical and temporal diversity, genetic enrichment, and dynamic associations
with the host microbiome. mBio 2015, 6, e01578-15. [CrossRef] [PubMed]
23. Probst, A.J.; Auerbach, A.K.; Moissl-Eichinger, C. Archaea on Human Skin. PLoS ONE 2013, 8, e65388. [CrossRef] [PubMed]
24. Faergemann, J.; Larkö, O. The effect of UV-light on human skin microorganisms. Acta Derm. Venereol. 1987, 67, 69–72. [PubMed]
25. Skowron, K.; Bauza-Kaszewska, J.; Kraszewska, Z.; Wiktorczyk-Kapischke, N.; Grudlewska-Buda, K.; Kwiecińska-Piróg, J.;
Wałecka-Zacharska, E.; Radtke, L.; Gospodarek-Komkowska, E. Human Skin Microbiome: Impact of Intrinsic and Extrinsic
Factors on Skin Microbiota. Microorganisms 2021, 9, 543. [CrossRef]
26. Gannesen, A.V.; Borrel, V.; Lefeuvre, L.; Netrusov, A.I.; Plakunov, V.K.; Feuilloley, M.G.J. Effect of two cosmetic compounds on
the growth, biofilm formation activity, and surface properties of acneic strains of Cutibacterium acnes and Staphylococcus aureus.
Microbiologyopen 2019, 8, e00659. [CrossRef]
27. Staudinger, T.; Pipal, A.; Redl, B. Molecular analysis of the prevalent microbiota of human male and female forehead skin
compared to forearm skin and the influence of make-up. J. Appl. Microbiol. 2011, 110, 1381–1389. [CrossRef]
28. Borrel, V.; Gannesen, A.V.; Barreau, M.; Gaviard, C.; Duclairoir-Poc, C.; Hardouin, J.; Konto-Ghiorghi, Y.; Lefeuvre, L.; Feuilloley,
M.G.J. Adaptation of acneic and non acneic strains of Cutibacterium acnes to sebum-like environment. Microbiologyopen 2019,
8, e00841. [CrossRef]
29. Borrel, V.; Thomas, P.; Catovic, C.; Racine, P.-J.; Konto-Ghiorghi, Y.; Lefeuvre, L.; Duclairoir-Poc, C.; Zouboulis, C.C.; Feuilloley,
M.G.J. Acne and Stress: Impact of Catecholamines on Cutibacterium acnes. Front. Med. 2019, 6, 155. [CrossRef]
30. Zouboulis, C.C.; Benhadou, F.; Byrd, A.S.; Chandran, N.S.; Giamarellos-Bourboulis, E.J.; Fabbrocini, G.; Frew, J.W.; Fujita, H.;
González-López, M.A.; Guillem, P.; et al. What causes hidradenitis suppurativa?—15 years after. Exp. Dermatol. 2020, 29,
1154–1170. [CrossRef]
31. Ring, H.C.; Thorsen, J.; Saunte, D.M.; Lilje, B.; Bay, L.; Riis, P.T.; Larsen, N.; Andersen, L.O.; Nielsen, H.V.; Miller, I.M.; et al. The
Follicular Skin Microbiome in Patients with Hidradenitis Suppurativa and Healthy Controls. JAMA Dermatol. 2017, 153, 897–905.
[CrossRef]
32. Wark, K.J.L.; Cains, G.D. The Microbiome in Hidradenitis Suppurativa: A Review. Dermatol. Ther. 2021, 11, 39–52. [CrossRef]
33. Scholz, C.F.P.; Kilian, M. The natural history of cutaneous propionibacteria, and reclassification of selected species within
the genus Propionibacterium to the proposed novel genera Acidipropionibacterium gen. nov., Cutibacterium gen. nov. and
Pseudopropionibacterium gen. nov. Int. J. Syst. Evol. Microbiol. 2016, 66, 4422–4432. [CrossRef]
34. Dekio, I.; McDowell, A.; Sakamoto, M.; Tomida, S.; Ohkuma, M. Proposal of new combination, Cutibacterium acnes subsp.
elongatum comb. nov., and emended descriptions of the genus Cutibacterium, Cutibacterium acnes subsp. acnes and Cutibacterium
acnes subsp. defendens. Int. J. Syst. Evol. Microbiol. 2019, 69, 1087–1092. [CrossRef]
35. Patel, A.; Calfee, R.P.; Plante, M.; Fischer, S.A.; Green, A. Propionibacterium acnes colonization of the human shoulder. J. Shoulder
Elb. Surg 2009, 18, 897–902. [CrossRef]
36. Fitz-Gibbon, S.; Tomida, S.; Chiu, B.H.; Nguyen, L.; Du, C.; Liu, M.; Elashoff, D.; Erfe, M.C.; Loncaric, A.; Kim, J.; et al.
Propionibacterium acnes strain populations in the human skin microbiome associated with acne. J. Investig. Dermatol. 2013, 133,
2152–2160. [CrossRef]
37. Barnard, E.; Shi, B.; Kang, D.; Craft, N.; Li, H. The balance of metagenomic elements shapes the skin microbiome in acne and
health. Sci. Rep. 2016, 6, 39491. [CrossRef]
38. Tomida, S.; Nguyen, L.; Chiu, B.H.; Liu, J.; Sodergren, E.; Weinstock, G.M.; Li, H. Pan-genome and comparative genome
analyses of propionibacterium acnes reveal its genomic diversity in the healthy and diseased human skin microbiome. mBio 2013,
4, e00003-13. [CrossRef]
Life 2022, 12, 422 10 of 11
39. Schaller, M.; Loewenstein, M.; Borelli, C.; Jacob, K.; Vogeser, M.; Burgdorf, W.H.; Plewig, G. Induction of a chemoattractive
proinflammatory cytokine response after stimulation of keratinocytes with Propionibacterium acnes and coproporphyrin III. Br. J.
Dermatol. 2005, 153, 66–71. [CrossRef]
40. Nagy, I.; Pivarcsi, A.; Koreck, A.; Széll, M.; Urbán, E.; Kemény, L. Distinct strains of Propionibacterium acnes induce selective
human beta-defensin-2 and interleukin-8 expression in human keratinocytes through toll-like receptors. J. Investig. Dermatol.
2005, 124, 931–938. [CrossRef]
41. Yu, Y.; Champer, J.; Agak, G.W.; Kao, S.; Modlin, R.L.; Kim, J. Different Propionibacterium acnes Phylotypes Induce Distinct Immune
Responses and Express Unique Surface and Secreted Proteomes. J. Investig. Dermatol. 2016, 136, 2221–2228. [CrossRef] [PubMed]
42. Dréno, B. What is new in the pathophysiology of acne, an overview. J. Eur. Acad Dermatol. Venereol. 2017, 31 (Suppl. S5), 8–12.
[CrossRef] [PubMed]
43. Beylot, C.; Auffret, N.; Poli, F.; Claudel, J.P.; Leccia, M.T.; Del Giudice, P.; Dreno, B. Propionibacterium acnes: An update on its
role in the pathogenesis of acne. J. Eur. Acad Dermatol. Venereol. 2014, 28, 271–278. [CrossRef] [PubMed]
44. Das, S.; Reynolds, R.V. Recent advances in acne pathogenesis: Implications for therapy. Am. J. Clin. Dermatol. 2014, 15, 479–488.
[CrossRef] [PubMed]
45. Goodfellow, A.; Alaghband-Zadeh, J.; Carter, G.; Cream, J.J.; Holland, S.; Scully, J.; Wise, P. Oral spironolactone improves acne
vulgaris and reduces sebum excretion. Br. J. Dermatol. 1984, 111, 209–214. [CrossRef] [PubMed]
46. Moradi Tuchayi, S.; Makrantonaki, E.; Ganceviciene, R.; Dessinioti, C.; Feldman, S.R.; Zouboulis, C.C. Acne vulgaris. Nat. Rev.
Dis. Primers 2015, 1, 15029. [CrossRef]
47. Whiteside, J.A.; Voss, J.G. Incidence and lipolytic activity of Propionibacterium acnes (Corynebacterium acnes group I) and P. granulo-
sum (C. acnes group II) in acne and in normal skin. J. Investig. Dermatol. 1973, 60, 94–97. [CrossRef] [PubMed]
48. Hu, G.; Wei, Y.P.; Feng, J. Malassezia infection: Is there any chance or necessity in refractory acne? Chin. Med. J. 2010, 123, 628–632.
49. Katsuta, Y.; Iida, T.; Inomata, S.; Denda, M. Unsaturated fatty acids induce calcium influx into keratinocytes and cause abnormal
differentiation of epidermis. J. Investig. Dermatol. 2005, 124, 1008–1013. [CrossRef]
50. Benson, K.F.; Redman, K.A.; Carter, S.G.; Keller, D.; Farmer, S.; Endres, J.R.; Jensen, G.S. Probiotic metabolites from Bacillus
coagulans GanedenBC30™ support maturation of antigen-presenting cells in vitro. World J. Gastroenterol. 2012, 18, 1875–1883.
[CrossRef]
51. Salvucci, E. Microbiome, holobiont and the net of life. Crit. Rev. Microbiol. 2016, 42, 485–494. [CrossRef] [PubMed]
52. Lee, Y.B.; Byun, E.J.; Kim, H.S. Potential Role of the Microbiome in Acne: A Comprehensive Review. J. Clin. Med. 2019, 8, 987.
[CrossRef] [PubMed]
53. Bowe, W.; Patel, N.B.; Logan, A.C. Acne vulgaris, probiotics and the gut-brain-skin axis: From anecdote to translational medicine.
Benef. Microbes 2014, 5, 185–199. [CrossRef] [PubMed]
54. Salem, I.; Ramser, A.; Isham, N.; Ghannoum, M.A. The Gut Microbiome as a Major Regulator of the Gut-Skin Axis. Front.
Microbiol. 2018, 9, 1459. [CrossRef]
55. Loveman, D.E.; Noojin, R.O.; Winkler, C.H., Jr. Comparative studies of enteric bacterial flora in acne vulgaris. J. Investig. Dermatol.
1955, 25, 135–137. [CrossRef]
56. Volkova, L.A.; Khalif, I.L.; Kabanova, I.N. Impact of the impaired intestinal microflora on the course of acne vulgaris. Klin. Med.
2001, 79, 39–41.
57. Deng, Y.; Wang, H.; Zhou, J.; Mou, Y.; Wang, G.; Xiong, X. Patients with Acne Vulgaris Have a Distinct Gut Microbiota in
Comparison with Healthy Controls. Acta Derm. Venereol. 2018, 98, 783–790. [CrossRef]
58. Yan, H.M.; Zhao, H.J.; Guo, D.Y.; Zhu, P.Q.; Zhang, C.L.; Jiang, W. Gut microbiota alterations in moderate to severe acne vulgaris
patients. J. Dermatol. 2018, 45, 1166–1171. [CrossRef]
59. Hill, C.; Guarner, F.; Reid, G.; Gibson, G.R.; Merenstein, D.J.; Pot, B.; Morelli, L.; Canani, R.B.; Flint, H.J.; Salminen, S.; et al. The
International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the
term probiotic. Nat. Rev. Gastroenterol. Hepatol. 2014, 11, 506–514. [CrossRef]
60. Rusu, E.; Enache, G.; Cursaru, R.; Alexescu, A.; Radu, R.; Onila, O.; Cavallioti, T.; Rusu, F.; Posea, M.; Jinga, M.; et al. Prebiotics
and probiotics in atopic dermatitis. Exp. Ther. Med. 2019, 18, 926–931. [CrossRef]
61. Fanfaret, I.S.; Boda, D.; Ion, L.M.; Hosseyni, D.; Leru, P.; Ali, S.; Corcea, S.; Bumbacea, R. Probiotics and prebiotics in atopic
dermatitis: Pros and cons (Review). Exp. Ther. Med. 2021, 22, 1376. [CrossRef] [PubMed]
62. Gasbarrini, G.; Bonvicini, F.; Gramenzi, A. Probiotics History. J. Clin. Gastroenterol. 2016, 50 (Suppl. S2), S116–S119. [CrossRef]
[PubMed]
63. França, K. Topical Probiotics in Dermatological Therapy and Skincare: A Concise Review. Dermatol. Ther. 2021, 11, 71–77.
[CrossRef] [PubMed]
64. Lee, G.R.; Maarouf, M.; Hendricks, A.J.; Lee, D.E.; Shi, V.Y. Topical probiotics: The unknowns behind their rising popularity.
Derm. Online J. 2019, 25, 5. [CrossRef]
65. Puebla-Barragan, S.; Reid, G. Probiotics in Cosmetic and Personal Care Products: Trends and Challenges. Molecules 2021, 26, 1249.
[CrossRef]
66. Salminen, S.; Collado, M.C.; Endo, A.; Hill, C.; Lebeer, S.; Quigley, E.M.M.; Sanders, M.E.; Shamir, R.; Swann, J.R.; Szajewska, H.;
et al. The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and
scope of postbiotics. Nat. Rev. Gastroenterol. Hepatol. 2021, 18, 649–667. [CrossRef]
Life 2022, 12, 422 11 of 11
67. Report of the ICCR: ICCR Microbiome and Cosmetics—Survey of Products Ingredients Terminologies and Regulatory Approach.
2021. Available online: https://www.iccr-cosmetics.org/ (accessed on 1 March 2022).
68. Reisch, M.S. Cosmetics: The next microbiome frontier. Mitsui Chem. Catal. Sci. Award. 2017, 95, 30–34.
69. Fuchs-Tarlovsky, V.; Marquez-Barba, M.F.; Sriram, K. Probiotics in dermatologic practice. Nutrition 2016, 32, 289–295. [CrossRef]
70. Nowicka, D.; Chilicka, K.; Dzieńdziora-Urbińska, I. Host-Microbe Interaction on the Skin and Its Role in the Pathogenesis and
Treatment of Atopic Dermatitis. Pathogens 2022, 11, 71. [CrossRef]
71. Nowicka, D.; Grywalska, E. Staphylococcus aureus and host Immunity in recurrent furunculosis. Dermatology 2019, 235, 295–305.
[CrossRef]
72. Di Marzio, L.; Cinque, B.; De Simone, C.; Cifone, M.G. Effect of the lactic acid bacterium Streptococcus thermophilus on ceramide
levels in human keratinocytes in vitro and stratum corneum in vivo. J. Investig. Dermatol. 1999, 113, 98–106. [CrossRef] [PubMed]
73. Bowe, W.P.; Logan, A.C. Acne vulgaris, probiotics and the gut-brain-skin axis—Back to the future? Gut Pathog. 2011, 3, 1.
[CrossRef] [PubMed]
74. Kang, B.S.; Seo, J.G.; Lee, G.S.; Kim, J.H.; Kim, S.Y.; Han, Y.W.; Kang, H.; Kim, H.O.; Rhee, J.H.; Chung, M.J.; et al. Antimicrobial
activity of enterocins from Enterococcus faecalis SL-5 against Propionibacterium acnes, the causative agent in acne vulgaris, and
its therapeutic effect. J. Microbiol. 2009, 47, 101–109. [CrossRef]
75. Brook, I. Bacterial interference. Crit. Rev. Microbiol. 1999, 25, 155–172. [CrossRef]
76. Kurkowska, N.; Musiał, C. Probiotics in acne skin care. A review of the latest scientific reports. Aesthetic Cosmetol. Med. 2021,
2, 91–98. [CrossRef]
77. Kurzekar, N.; Waseule, D. Probiotics in skin care products—A review. IJRTI 2018, 3, 166–175.
78. Al-Ghazzewi, F.H.; Tester, R.F. Impact of prebiotics and probiotics on skin health. Benef. Microbes 2014, 5, 99–107. [CrossRef]
79. Zommiti, M.; Feuilloley, M.G.J.; Connil, N. Update of Probiotics in Human World: A Nonstop Source of Benefactions till the End
of Time. Microorganisms 2020, 8, 1907. [CrossRef]
80. Jung, G.W.; Tse, J.E.; Guiha, I.; Rao, J. Prospective, randomized, open-label trial comparing the safety, efficacy, and tolerability of
an acne treatment regimen with and without a probiotic supplement and minocycline in subjects with mild to moderate acne.
J. Cutan. Med. Surg. 2013, 17, 114–122. [CrossRef]
81. Al-Ghazzewi, F.H.; Tester, R.F. Effect of konjac glucomannan hydrolysates and probiotics on the growth of the skin bacterium
Propionibacterium acnes in vitro. Int. J. Cosmet. Sci. 2010, 32, 139–142. [CrossRef]
82. Tsai, W.-H.; Chou, C.-H.; Chiang, Y.-J.; Lin, C.-G.; Lee, C.-H. Regulatory effects of Lactobacillus plantarum-GMNL6 on human
skin health by improving skin microbiome. Int. J. Med. Sci. 2021, 18, 1114–1120. [CrossRef] [PubMed]
83. Espinoza-Monje, M.; Campos, J.; Alvarez Villamil, E.; Jerez, A.; DenticeMaidana, S.; Elean, M.; Salva, S.; Kitazawa, H.; Villena, J.;
García-Cancino, A. Characterization of Weissellaviridescens UCO-SMC3 as a Potential Probiotic for the Skin: Its Beneficial Role
in the Pathogenesis of Acne Vulgaris. Microorganisms 2021, 9, 1486. [CrossRef] [PubMed]
84. Kim, J.; Kim, H.; Jeon, S.; Jo, J.; Kim, Y.; Kim, H. Synergistic Antibacterial Effects of Probiotic Lactic Acid Bacteria with Curcuma
longa Rhizome Extract as Synbiotic against Cutibacterium acnes. Appl. Sci. 2020, 10, 8955. [CrossRef]